Medicine and Dentistry
Anthracycline
66%
Cardiotoxicity
66%
Interstitial Lung Disease
66%
Cardiac Troponin
42%
Troponin I
42%
Heart Left Ventricle Ejection Fraction
42%
Beta Adrenergic Receptor Blocking Agent
42%
Randomized Controlled Trial
33%
Receptor Blocking
33%
Angiotensin Receptor
33%
Troponin
33%
Heart Left Ventricle Failure
18%
Carvedilol
17%
Candesartan
17%
Breast Cancer
17%
Heart Protection
16%
Disease Course
16%
Renin-Angiotensin System Inhibitor
13%
Quality of Life
11%
Heart Muscle Injury
9%
Non-Hodgkin Lymphoma
8%
Cardiac Magnetic Resonance Imaging
8%
Dyspnea
5%
Lung
5%
Chronic Lung Disease
5%
Infection
5%
Oxygen Consumption
5%
Pediatrics
5%
Patient-Reported Outcome
5%
Pulmonary Disorder
5%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
100%
Cardiotoxicity
77%
Troponin I
76%
Chemotherapy
73%
Troponin
62%
Beta Adrenergic Receptor Blocking Agent
42%
Randomized Controlled Trial
33%
Angiotensin Receptor
33%
Breast Cancer
28%
Heart Muscle Injury
20%
Heart Left Ventricle Failure
18%
Candesartan
17%
Carvedilol
17%
Renin-Angiotensin System Inhibitor
13%
Epirubicin
11%
Nonhodgkin Lymphoma
8%
Malignant Neoplasm
5%
Cohort Study
5%
Iatrogenic Disease
5%
Nursing and Health Professions
Anthracycline
33%
Receptor Blocking
33%
Angiotensin Receptor
33%
Troponin I
33%
Troponin
16%
Cardiotoxicity
11%
Breast Cancer
11%
Heart Muscle Injury
11%
Blood Sampling
11%
Epirubicin
11%
Candesartan
9%
Cohort Analysis
5%
Female Patient
5%
Cancer Therapy
5%
Iatrogenesis
5%
Malignant Neoplasm
5%
